Alzheimer’s Disease: Therapeutics
Alzheimer’s Disease (AD) presents many challenges at the individual, family and health system levels. From the therapeutics perspective, AD presents the highest failure rate for drug development of any disease indication being studied today. However, there are many new pathways being explored to both optimize drug development, clinical trial recruitment, understand disease pathogenesis and much more. In the same way that AD is a multifactorial disease, so must be the solutions to therapeutic development. In this week’s Deep Dive, we will explore the state of Alzheimer’s Disease therapeutics development, where the cutting edge research is today and the major challenges that prevail today.
- Early Alzheimer’s Disease: Developing Drugs for Treatment Guidance for Industry
- Scientists Say They Have Developed A Memory-Restoring Prosthetic For The Human Brain
- FDA-approved treatments for Alzheimer’s
- Treatment Horizon
- A Vast Unmet Need: Challenges In Alzheimer’s Clinical Trials
- Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done?
- Alzheimer's Drugs in Development Pipeline
- Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update
- Alzheimer's disease drug development pipeline: 2018
- Alzheimer's Drug Trials Keep Failing -- It May Be Because We Don't Understand the Disease
- Azeliragon: The third Alzheimer’s failure of 2018
- CLOSING IN ON A CURE: 2017 Alzheimer's Clinical Trials Report
- Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer’s Disease?